Amyloid Day in Calgary 2022

Join us for the fourth annual Amyloid Day on Oct. 20, 2022. This year's event will be held virtually in Calgary, Alberta. 

Event description

This year’s event is dedicated to our mentors and educators in amyloidosis. We are here because of you! 

Over the past few years there have been tremendous advances in amyloidosis care, both recognition and diagnostic approaches, and importantly, new and/or enhanced therapeutic strategies. Because amyloidosis is a relatively rare multi-system disorder, a multi-disciplinary team approach has been demonstrated at other medical centres to be the optimal model of care.

Based on the above, we have established a group in Calgary aiming to provide with care and the infrastructure for the diagnosis and treatment of this entity. On behalf of the Amyloidosis Program of Calgary (APC), it is a pleasure to invite you to attend the fourth annual International Amyloid day in Calgary to be held on Oct. 20, 2022.

Please see below for an agenda. Zoom details to come.  

Contact: Jan Veenhuyzen

amyloidosis image


Please note: to view the full agenda, please click on the drop-down menu below and select 'Show all 14 entries'.  Alternatively, you may click on the number 2 at the bottom of the agenda to view the afternoon sessions listed on page 2.

Time What's Happening Zoom Details 
7:30 am  "Nursing and Amyloid" – Lisa Mendelson – University of Boston, USA  
8:00 am Opening remarks  Dr. Victor Jimenez-Zepeda – Amyloidosis Program of Calgary, University of Calgary, Canada   
8:15 am “Cardiac Imaging in the Diagnosis and Monitoring of Amyloidosis" – Dr. Marianna Fontana - National Amyloid Center, UK   
9:00 am “Novel Non-transplant Approaches for the Treatment of AL Amyloidosis” – Dr. Stefan Schoenland – Heidelberg Amyloid Center, Germany   
9:45 am

AL Breakout Session: 

Pathology and Amyloidosis – Dr. Etienne Mahe – University of Calgary

Role of the Pharmacist – Nikki Blosser – Tom Baker Cancer Centre, Calgary, AB

Ask the Expert – Dr. Victor Jimenez-Zepeda – Amyloidosis Program of Calgary, University of Calgary

10:15 am Break  
10:30 am “Impact of Cytogenetics for AL Amyloidosis" – Dr. Rafael Fonseca – Mayo Clinic, Arizona, USA   
11:15 am “Transplant Strategies for the Treatment of AL Amyloidosis” – Dr. Efstathios Kastritis – National and Kapodistrian University of Athens, Greece   
12:00 pm "AL Amyloidosis: My Personal Journey" – Dr. Morie Gertz – Mayo Clinic, Minnesota, USA   
1:00 pm Lunch Break Tribute to Marsha McWhinnie  
1:30 pm “Novel Therapies for ATTR; An Introduction to CRISPR-Cas9 In Vivo Gene Editing” – Dr. Julian Gillmore - National Amyloid Center, UK  
2:15 pm

ATTR Breakout Session:

Genetic Counselling – Cathleen Huculak – Alberta Health Services

Ask the Expert – Dr. Shahin Khayambashi – University of British Columbia

Patient/Caregiver support – Anne Marie Carr – Hereditary Amyloidosis Canada (HAC)

2:45 pm “Modern Approaches for Assessing Response to Therapy and Disease Progression for ATTR-CM” – Dr. Mathew Maurer – Columbia University, USA   
3:30 pm Closing remarks – Dr. Nowell Fine – Amyloidosis Program of Calgary, University of Calgary, Canada  


Dr. Victor H Jimenez-Zepeda

Dr. Victor H Jimenez-Zepeda

Dr. Victor H Jimenez-Zepeda is an associate professor of Medicine in the Cumming School of Medicine at the University of Calgary. He is co-director of the Amyloidosis Program of Calgary and leads the clinical program for AL amyloidosis at the Tom Baker Cancer Center in Calgary. Dr. Jimenez-Zepeda is a member of the Calgary transplant group and the Multiple Myeloma Program.

Dr. Mathew S. Maurer

Dr. Mathew S. Maurer

Dr. Mathew S. Maurer, MD, is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where he directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr. Maurer has published more than 300 peer reviewed publications and was Chair of the American College of Cardiology’s Geriatric Cardiology Member Section, co-chair of the Steering Committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for transthyretin amyloid cardiomyopathy.

Dr. Efstathios Kastritis

Dr. Efstathios Kastritis

Dr. Efstathios Kastritis is an associate professor of Clinical Therapeutics/Medical Oncology at the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens in the School of Medicine.

Dr. Stefan Schonland

Dr. Stefan Schonland

Dr. Stefan Schonland is a medical oncologist member of the WorkingGroup for Amyloidosis Diseases Heidelberg and the Task Force Leader Amyloidosis of the Medical Clinic V.

Dr. Marianna Fontana

Dr. Marianna Fontana

Dr. Marianna Fontana is the director of the UCL CMR unit at the Royal Free Hospital. She is associate professor and honorary consultant cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, where she is deputy head of Center and deputy clinical lead.

Dr. Rafael Fonseca

Dr. Rafael Fonseca

Dr. Rafael Fonseca is a professor of Medicine at the Mayo Clinic College of Medicine and Science in Arizona and serves as a clinical investigator of the Damon Runyon Cancer Research Foundation. He earned his medical degree at the Universidad Anáhuac México prior to completing his residency (medicine) at the University of Miami.

Dr. Morie A. Gertz

Dr. Morie A. Gertz

Dr. Morie A. Gertz is the Roland Seidler Jr. Professor of the Art of Medicine at the Mayo Clinic in Rochester, Minnesota. He is a master of the American College of Physicians and a great mentor for many amyloidosis physicians that he has trained at the Mayo Clinic over the years.

Dr. Julian Gillmore

Dr. Julian Gillmore

Dr. Julian Gillmore is an internationally recognized scientist who is famous for his persistent work in the field of amyloidosis. He has specialized in this area during his MD and PhD programs, which were completed at Imperial College London (2001) and University College London (UCL, 2004), respectively.

Dr. Nowell Fine

Dr. Nowell Fine

Dr. Nowell Fine is a heart failure cardiologist and echocardiologist in Calgary, Alberta. He is an associate clinical professor of Cardiac Sciences, Medicine and Community Health Sciences at the Cumming School of Medicine, University of Calgary. He is the clinical director of the Libin Cardiovascular Institute.

Lisa Mendelson

Lisa Mendelson, NP

Lisa Mendelson has been a nurse practitioner at the Boston University Amyloidosis Center since 2017. She obtained her nurse practitioner degree from MGH Institute of Health Professions in 2010 and prior to coming to BU worked in private practice cardiology and hepatology in San Mateo, CA. In addition to her clinical practice she participates as a reviewer for multiple peer reviewed journals and has authored many publications with a focus on amyloidosis awareness. In her spare time she enjoys spending time with her dogs and gardening.

Dr. Etienne Mahe headshot

Dr. Etienne Mahe

Etienne Mahe is a pathologist in the division of Hematology of Calgary Lab Services. He has fellowship training in the application of NGS-based technologies to cancer testing. Dr. Mahe also has a strong interest in the genetics of B and T-cell clonality, as well as cutaneous lymphoproliferative disorders and AL amyloidosis. He has been pivotal in the implementation of an amyloid screening clinic based on biomarkers, bone marrow and fat pad aspirates. He is also a member of the Amyloidosis Program of Calgary.

Nikki Blosser headshot

Nikki Blosser

Nikki Blosser graduated from Memorial University School of Pharmacy in 2010 and then moved to Calgary to complete an Accredited Canadian Residency Program with a focus in oncology through the Canadian Society of Hospital Pharmacists. Since that time she has been working as a clinical pharmacist in the blood and marrow transplant program and hematology at the Tom Baker Cancer Centre and served as the interim clinical research pharmacist in the hematology, oncology and transplant clinic at Alberta Children's Hospital. She has an interest in survivorship and participates in research projects through the bmt, hematology, including our amyloid clinic.

Cathy Huculak

Cathy Huculak

Cathy Huculak is a Certified Genetic Counsellor with Clinical Genetics at the Alberta Children’s Hospital. She has the privilege of working with patients and families experiencing hereditary disorders at many clinics across Canada since completing her program at the University of British Columbia. For the past seven years, she has focused on inherited cardiomyopathies and arrhythmias, including amyloidosis.

Anne Marie Carr headshot

Anne Marie Carr

Anne Marie Carr is the Founder and CEO of Hereditary Amyloidosis Canada. She has been a tremendous advocate for patients and families affected by amyloidosis following her diagnosis of hereditary transthyretin amyloidosis in 2015. Anne Marie serves as an advisor and spokesperson to various amyloid groups and societies. 

Dr. Shahin Khayambashi headshot

Dr. Shahin Khayambashi

Dr. Shahin Khayambashi is a recent graduate of the University of Calgary Clinical Neuromuscular Fellowship program. He contributed to the Canadian guidelines on hereditary ATTR management. His research focus includes improving clinical, electrophysiologic and sonographic characterization of neuropathy in TTR amyloidosis.

Overall Program Learning Objectives

At the end of this session, participants will be able to:

  • Identify diagnostic algorithms most commonly used in the assessment of amyloidosis and use of this knowledge in the early identification of patients with features of organ involvement by amyloid deposition
  • Participants will be able to recognize the value of a Multidisciplinary Team (MDT) in the evaluation and treatment of patients with amyloidosis
  • Participants will be able to recognize the supportive care needed in the care of amyloidosis patients and establish this important pilar of management for suspected cases while the proper diagnosis and typing is achieved
  • Participants will be able to use this information to educate peers and primary physicians aiming to raise awareness of these entities that are considered rare disorders and often require multiple visits before diagnosis is established